Capricor Therap (CAPR)

Jun 3, 2025, 10:00 AM EDT - 2 days ago

Capricor Therapeutics, Inc. (CAPR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Jun 2, 2025, 10:00 AM EDT - 3 days ago

Bronstein, Gewirtz & Grossman, LLC Encourages Capricor Therapeutics, Inc. (CAPR) Shareholders to Inquire about Securities Investigation

Jun 1, 2025, 10:00 AM EDT - 4 days ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Capricor Therapeutics, Inc. (CAPR) And Encourages Shareholders to Connect

May 30, 2025, 10:00 AM EDT - 6 days ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Capricor Therapeutics, Inc. (CAPR) And Encourages Shareholders to Reach Out

May 29, 2025, 10:00 AM EDT - 7 days ago

Bronstein, Gewirtz & Grossman, LLC Encourages Capricor Therapeutics, Inc. (CAPR) Stockholders to Inquire about Securities Investigation

May 28, 2025, 10:00 AM EDT - 8 days ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Capricor Therapeutics, Inc. (CAPR) and Encourages Investors to Learn More About the Investigation

May 27, 2025, 10:00 AM EDT - 9 days ago

Capricor Therapeutics, Inc. (CAPR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

May 26, 2025, 10:00 AM EDT - 10 days ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Capricor Therapeutics, Inc. (CAPR) And Encourages Investors to Connect

May 23, 2025, 10:00 AM EDT - 13 days ago

Bronstein, Gewirtz & Grossman, LLC Encourages Capricor Therapeutics, Inc. (CAPR) Investors to Inquire about Securities Investigation

May 23, 2025, 2:44 AM EDT - 13 days ago

Capricor Therapeutics' Buy Thesis Ahead Of Deramiocel PDUFA Date

May 22, 2025, 10:00 AM EDT - 14 days ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Capricor Therapeutics, Inc. (CAPR) And Encourages Investors to Reach Out

May 22, 2025, 12:45 AM EDT - 14 days ago

Capricor: High-Reward DMD Treatment Bet With Strong Data And Looming FDA Decision

May 21, 2025, 10:00 AM EDT - 15 days ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Capricor Therapeutics, Inc. (CAPR) And Encourages Stockholders to Reach Out

May 20, 2025, 10:00 AM EDT - 16 days ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Capricor Therapeutics, Inc. (CAPR) And Encourages Stockholders to Connect

May 20, 2025, 5:47 AM EDT - 16 days ago

I Missed The Quantum Rally - I Won't Miss The Next One

AMSC AUTL CLPT EDIT NTLA VANI VERV

May 20, 2025, 5:26 AM EDT - 16 days ago

CAPR Investors Have Opportunity to Join Capricor Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

May 19, 2025, 11:00 AM EDT - 17 days ago

Capricor Therapeutics, Inc. (CAPR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

May 13, 2025, 8:36 PM EDT - 23 days ago

Capricor Therapeutics, Inc. (CAPR) Q1 2025 Earnings Conference Call Transcript

May 6, 2025, 9:15 AM EDT - 4 weeks ago

Capricor Therapeutics to Present First Quarter 2025 Financial Results and Recent Corporate Update on May 13

May 5, 2025, 11:08 AM EDT - 4 weeks ago

US FDA to convene expert panel for Capricor Therapeutics' DMD cell therapy

May 5, 2025, 8:00 AM EDT - 4 weeks ago

Capricor Therapeutics Announces Completion of Mid-Cycle Review Meeting with FDA on Deramiocel for the Treatment of Duchenne Muscular Dystrophy Cardiomyopathy

Mar 19, 2025, 6:56 PM EDT - 2 months ago

Capricor Therapeutics, Inc. (CAPR) Q4 2024 Earnings Call Transcript

Mar 19, 2025, 4:05 PM EDT - 2 months ago

Capricor Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Mar 17, 2025, 9:25 AM EDT - 2 months ago

Capricor Therapeutics Announces Positive Data Demonstrating Long-Term Efficacy of Deramiocel for the Treatment of Duchenne Muscular Dystrophy

Mar 10, 2025, 9:13 AM EDT - 3 months ago

FDA Accepts Biologics License Application for Duchenne Muscular Dystrophy Cardiomyopathy Treatment

Mar 7, 2025, 9:25 AM EST - 3 months ago

Capricor Therapeutics to Present at Leerink's Global Healthcare Conference 2025

Mar 4, 2025, 3:57 PM EST - 3 months ago

Capricor: Further Value Unlocked With Priority Review Of Deramiocel

Mar 4, 2025, 11:21 AM EST - 3 months ago

Capricor Therapeutics Cell Therapy Goes Under Priority FDA Review For Duchenne Associated-Heart Condition

Feb 23, 2025, 9:13 PM EST - 3 months ago

Capricor Therapeutics: Heavily Derisked After BLA Submission And OLE Data

Jan 2, 2025, 9:15 AM EST - 5 months ago

Capricor Therapeutics Completes Submission of Biologics License Application to the U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy

Dec 12, 2024, 12:08 PM EST - 6 months ago

RFK Jr. could prove a surprise boon for stem-cell stocks with pivotal year ahead

MESO XBI

Dec 7, 2024, 5:08 AM EST - 6 months ago

Deramiocel's Promise Brightens Capricor's Outlook, With Strings Attached

Dec 6, 2024, 8:00 AM EST - 6 months ago

Capricor: Additional Deramiocel Data Bodes Well For Initiated Rolling BLA Submission

Dec 2, 2024, 4:15 PM EST - 6 months ago

Capricor Therapeutics to Present at Upcoming Investor Conferences

Nov 13, 2024, 11:12 PM EST - 7 months ago

Capricor Therapeutics, Inc. (CAPR) Q3 2024 Earnings Call Transcript

Nov 13, 2024, 4:01 PM EST - 7 months ago

Capricor Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Oct 18, 2024, 4:01 PM EDT - 8 months ago

Capricor Therapeutics Announces Closing of Underwritten Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Oct 17, 2024, 6:00 AM EDT - 8 months ago

Capricor Therapeutics Announces Pricing of Approximately $75 Million Public Offering of Common Stock

Oct 16, 2024, 4:17 PM EDT - 8 months ago

Capricor Therapeutics Announces Proposed Public Offering of Common Stock

Oct 11, 2024, 9:15 AM EDT - 8 months ago

Capricor Therapeutics Announces Positive Long-Term Data from HOPE-2 OLE Study in Duchenne Muscular Dystrophy at 2024 World Muscle Society Congress

Oct 9, 2024, 9:15 AM EDT - 8 months ago

Capricor Therapeutics Announces Initiation of Rolling Submission of Biologics License Application (BLA) with U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy